Functions and tocopherol content of blood platelets from elderly people after low intake of purified eicosapentaenoic acid.
Elderly people present an increased incidence of atherosclerosis and vascular cerebral damages, associated with blood platelet hyperactivity and a stimulation of arachidonic acid metabolism in vivo. The effects of a low intake of purified eicosapentaenoic acid (EPA) on platelet hyperactivity in old human subjects has been investigated. In a randomized, double blind study, 8 people took during 2 months a daily intake of 100 mg of eicosapentaenoic acid (EPA) given as a triglyceride (1,3-dioctanoyl,2-eicosapentaenoyl-glycerol), and 8 other subjects ingested a placebo. A slight, but significant reduction of platelet-rich plasma aggregation in response to epinephrine and arachidonic acid occurred after EPA intake, as well as a decreased aggregation of washed platelets induced by thrombin, although collagen- and U-46619-induced aggregations were not significantly modified. EPA intake failed to affect arachidonic acid metabolism in thrombin-stimulated platelets or in clotted venous blood. The urinary excretion of thromboxane, 6-keto-PGF1 alpha and their 2,3-dinor-metabolites was also not modified. Similarly, no change in the plasma and platelet lipid fatty acid compositions could be observed. Platelet, but not plasma, alpha- and gamma-tocopherol were enhanced by EPA intake. An increase of platelet vitamin E has been associated with a decrease of aggregation, especially in vitamin E-deficient subjects, like elderly people. Therefore, low intake of EPA might have contributed to inhibit platelet aggregation by increasing cellular vitamin E.
Croset
M
M
INSERM U 205, Laboratoire de Chimie Biologique, INSA, Villeurbanne, France.
Véricel
E
E
Rigaud
M
M
Hanss
M
M
Courpron
P
P
Dechavanne
M
M
Lagarde
M
M
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001792:Blood Platelets / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002784:Cholesterol / Q000097:blood; D004032:Diet; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D005227:Fatty Acids / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D010975:Platelet Aggregation Inhibitors; D014280:Triglycerides / Q000097:blood; D014810:Vitamin E / Q000032:analysis / Q000097:blood / Q000378:metabolism*
D001095:Arachidonic Acids; D005227:Fatty Acids; D010975:Platelet Aggregation Inhibitors; D014280:Triglycerides; D014810:Vitamin E; D016718:Arachidonic Acid; D002784:Cholesterol; D015118:Eicosapentaenoic Acid